The Herpes Labialis (Oral Herpes) drugs in development market research report provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Herpes Labialis (Oral Herpes). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Herpes Labialis (Oral Herpes) by 11 companies/universities/institutes. The top development phase for Herpes Labialis (Oral Herpes) is preclinical with five drugs in that stage. The Herpes Labialis (Oral Herpes) pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Herpes Labialis (Oral Herpes) pipeline products market are: Vironova Medical, NanoViricides and AiCuris Anti-infective Cures.
The key targets in the Herpes Labialis (Oral Herpes) pipeline products market include Lipopolysaccharide, Interferon Alpha/Beta Receptor 1, and Interferon Alpha/Beta Receptor 2.
The key mechanisms of action in the Herpes Labialis (Oral Herpes) pipeline product include DNA Synthesis Inhibitor with one drug in Preclinical. The Herpes Labialis (Oral Herpes) pipeline products include five routes of administration with the top ROA being Topical and six key molecule types in the Herpes Labialis (Oral Herpes) pipeline products market including Small Molecule, and Synthetic Peptide.
Herpes Labialis (Oral Herpes) overview
Oral herpes is an infection of the lips, mouth, or gums by the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands, and painful swallowing. Treatment includes antiviral medications.
For a complete picture of Herpes Labialis (Oral Herpes)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
